Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chenodeoxycholic Acid→

Chenodeoxycholic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
474-25-9
Molecular formula
C24H40O4
Molecular weight
392.57 g/mol
Drug class
Primary bile acidfarnesoid X receptor (FXR) ligand and bile-acid metabolic substrate
Mechanism of action
Acts as an endogenous bile acid that facilitates intestinal absorption of dietary fats and fat-soluble vitamins. It also activates FXR and regulates bile-acid synthesis and transport. Therapeutic effects in cerebrotendinous xanthomatosis (CTX) involve replacement of deficient bile-acid feedback and suppression of abnormal bile-acid precursor synthesis.
Indications / reported uses
  • Treatment of cerebrotendinous xanthomatosis (CTX) in adults and eligible paediatric patients using authorised chenodeoxycholic acid products; other gallstone-dissolution uses are historical or product-specific and should not be assumed

Sources: EMA EPAR — Chenodeoxycholic acid Leadiant · NLM MeSH — Chenodeoxycholic acid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chenodeoxycholic Acid Environmental Risk Assessment (ERA) (the Chenodeoxycholic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.